Are you prepared for when the FDA arrives at your facility?
FDA inspections, 483s and Warning Letters are part of the FDA’s regulatory process to ensure that products created by manufacturers are safe for consumers. FDA inspections involve visiting a manufacturer’s facility to evaluate if they are in compliance with FDA regulations
When the FDA arrives to inspect your facility, it’s important to stay calm and be prepared. The best way to do this is by having a plan in place ahead of time that outlines what steps need to be taken when an inspection occurs.
First, you should familiarize yourself with current regulations and inspect all areas of your facility for compliance. This includes verifying documentation, checking for any potential contamination sources, testing equipment, and ensuring proper labeling and packaging. You should also ensure that any relevant personnel are available to answer any questions from the auditors.
Once the inspection begins, it’s important to remain professional and courteous. Be sure to provide accurate information in response to their questions and cooperate fully with their requests. It’s also important to keep detailed records of all interactions, as the FDA may request this information at a later date.
Finally, if you have any concerns about the audit or the results, be sure to raise these issues with the FDA investigator and document them for future reference. The FDA can provide additional guidance on how to handle any discrepancies that arise during an audit and can help ensure your facility is compliant with all regulations. Discuss any questions about inspection observations with the FDA investigator and document your understanding of the concerns. Your company remains responsible for evaluating the findings, correcting deficiencies, and maintaining compliance.
A documented inspection plan, trained personnel, and organized records can help your team respond effectively when FDA arrives. Preparation supports inspection readiness, but it does not guarantee a particular outcome or eliminate the possibility of observations.
Click here to watch Part 2 of our VP Troy Fugate go into further detail on what to do when the FDA arrives.